Henan Shangheng Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the bioequivalence of fexofenadine hydrochloride oral suspension (trade name: Children’s Allegra Allergy, specification: 30mg/5ml) from Chattem, Inc., d/b/a Sanofi Consumer Healthcare as the reference preparation and fexofenadine hydrochloride oral suspension (specification: 120ml: 720mg) developed by Henan Shangheng Pharmaceutical Technology Co., Ltd. as the test preparation in Chinese healthy subjects in fasting and fed state. Secondary objective: To observe the safety of the test preparation and reference preparation in Chinese healthy subjects.

Primary objective: To evaluate the bioequivalence of the two preparations in the fasting and fed state in healthy Chinese subjects through a single-center, randomized, open, single-dose, two-preparation, three-sequence, three-period, partially repeated crossover clinical trial, using the reference preparation of Ezetimibe Atorvastatin Calcium Tablets (trade name: Atozet®, specification: each tablet contains 10 mg ezetimibe and 20 mg atorvastatin) produced by the licensee Organon Healthcare GmbH as the reference preparation and the test preparation of Ezetimibe Atorvastatin Calcium Tablets (each tablet contains 10 mg ezetimibe and 20 mg atorvastatin) produced by Henan Shangheng Pharmaceutical Technology Co., Ltd. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.